Aortic Aneurysm Market: Market Size & Forecast 2026

The aortic aneurysm market covers medical devices, pharmaceuticals, imaging diagnostics, and surgical services used to identify and treat aneurysmal dilation of the aorta. The two principal clinical segments are abdominal aortic aneurysm (AAA), which accounts for the majority of diagnosed cases, and thoracic aortic aneurysm (TAA), which includes conditions such as aortic dissection. From a $5.0 billion base in 2025, the market is on track to roughly $7.4 billion by 2030 on a 5.5% CAGR, with some longer-horizon outlooks placing it closer to $10.1 billion by the same year.

• •Market size in 2025: approximately $5.0 billion
• •Forecast CAGR through 2030: ~5.5%
• •Projected 2030 value: $7.4-$10.1 billion depending on forecast

Population aging is the single largest structural driver because aneurysm prevalence rises sharply after age 65, with risk factors such as hypertension, smoking, atherosclerosis, and connective-tissue disorders compounding the patient pool. Wider use of ultrasound screening programs and improved cross-sectional imaging (CT, MRI) is detecting more aneurysms earlier, enlarging the addressable treatment population. Simultaneously, the migration from open surgical repair toward endovascular aneurysm repair (EVAR) is expanding procedure volumes by offering lower-risk options for older and comorbid patients.

• •Rising prevalence tied to aging populations and cardiovascular risk factors
• •Expanded AAA screening and improved imaging increasing early detection
• •Shift from open repair to minimally invasive EVAR broadening the treated population

By type, abdominal aortic aneurysm represents the larger and more mature segment, while thoracic aortic aneurysm is growing faster due to better awareness and more complex stent-graft solutions. By treatment, open surgical repair still contributes meaningful revenue, but EVAR is the faster-growing segment and the primary focus of device innovation. Geographically, North America leads on the strength of screening programs, reimbursement, and procedure volumes, followed by Europe, while Asia-Pacific is the highest-growth region as healthcare access, imaging capacity, and vascular surgery infrastructure expand in China, India, and Japan.

• •Type: AAA dominates case volume; TAA growing faster off a smaller base
• •Treatment: EVAR is the fastest-expanding modality, with stent grafts leading product growth
• •Region: North America leads today; Asia-Pacific is the fastest-growing market

What are the recent trends and outlook?

The most important structural trend is the continued shift toward endovascular repair using low-profile and custom-made fenestrated and branched stent grafts that extend EVAR into more complex anatomies. Adjacent innovation is accelerating in adjunctive diagnostics, AI-assisted CT angiography for aneurysm measurement and surveillance, and earlier genetic screening for hereditary aortopathies. Over the remainder of the decade, the market is expected to keep mid-single-digit growth as procedure volumes rise faster than average selling prices, with Asia-Pacific contributing an outsized share of new demand.

• •Branched and fenestrated stent grafts expanding EVAR to complex anatomies
• •AI-enabled imaging improving diagnosis, sizing, and post-operative surveillance
• •Asia-Pacific set to contribute the largest incremental demand through 2030